TZ jags second Microsoft-backed sale for data centre locking kits
The kits from this order are destined for data centres in Europe, the Middle East and Africa.
The new deal is worth about US$156,000 (A$240,000) and adds to an earlier 120-kit purchase for Microsoft's United States operations revealed earlier this month. The latest order takes TZ's total Microsoft-backed sales so far to US$362,500 (A$585,000).
The order is part of a broader 360-unit commitment worth $725,000 to install a high-tech locking solution on Microsoft's server cabinets in data centres around the globe. It also represents the start of a commercial rollout of the company's retrofit solution to the high-security data centre market.
TZ's kits are powered by the company's proprietary slide handle smart locking system, which blends a futuristic shape memory alloy (SMA) with microprocessors to create a unique electronic locking system.
Known as the 'SMArt' system, the technology has dispensed with clunky keys in favour of a sleek, software-powered solution that puts control at a user's fingertips, offering tougher security and remotely controllable access with the push of a button or a card tap.
The lock comes with TZ's API-driven software combined with PortLink connectivity units and all the hardware needed to bolt into existing cabinet infrastructure.
The kits were specifically designed as a retrofit solution to deliver upgraded rack-level security, which can integrate seamlessly with Microsoft's broader access control platforms.
The Microsoft deal followed top-notch results from pilot installations at data centres in Dublin and Chicago and comes hot on the heels of the tech giant's recently reported plans to spend US$80 billion to expand its global data centre footprint.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
an hour ago
- News.com.au
Overseas travel to US continues to tumble as Trump imposes travel bans, tariffs
Travel to the US tumbled in July with the latest in a slew of monthly declines as the Trump administration imposes strict curbs on travel and pursues tough negotiations on trade. The 3.1 per cent drop was fuelled by a steep pullback from Germany, China and Switzerland, which were down 14.7 per cent, 13.8 per cent and 12.7 per cent respectively, according to the National Travel and Tourism Office, a government agency that works with the Department of Homeland Security and US Customs and Border Protection. The latest data does not include travel from Canada and Mexico, the two largest feeder markets to the US, but lately both have seen steep drops. Canadians in particular have been cancelling trips to the US, offended by President Trump's suggestion that they be annexed to the US as the 51st state. In June, flights from Canada were down 22 per cent and car crossings were down 33 per cent, according to a report by travel trade publication Skift. April represents the only exception to the downward trend, possibly because Easter fell in April instead of March. Overseas visitors increased 0.4 per cent in April, but have been down since then. Among the top 20 countries, six increased their travel to the US in July, including Japan by 9.1 per cent, Dominican Republic, by 7.3 per cent, Spain by 6.7 per cent Italy, by 6.3 per cent, Israel by 6.1 per cent and Ireland up by 2.9 per cent, according to NTTO. Spending on promoting the US as a destination was decimated after the 'Big Beautiful Bill' was passed in April. Brand USA, a public-private partnership that promotes travel in the US, saw its federal funds cut by 80 per cent this year. International travellers are especially coveted because they spend more and stay longer. Every 40 international visit supports one US job, according to NTTO. Last week, the largest hotel company in the world, Marriott International, cut its full year forecast for revenue and profits on slowing travel demand for its properties in the US.
News.com.au
4 hours ago
- News.com.au
Morgans spotlights nine healthcare stocks with upcoming catalysts after 'upbeat' Bioshares Biotech Summit
Morgans' Scott Power describes mood at Bioshares Biotech Summit as "markedly more upbeat than prior years" with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-term catalysts over next three to six months Results from Argenica's phase II trial of lead product ARG-007 in acute ischaemic stroke patients expected in early September In a further positive sign the ASX healthcare sector may be recovering, Morgans' senior healthcare analyst Scott Power has returned from the 19th annual Bioshares Biotech Summit, describing the mood of presenting companies as "markedly more upbeat than prior years". The summit, which featured presentations from more than 30 biotech companies, followed a strong July for the healthcare sector, which rose 9.05% to be best performer of the 11 ASX sectors. While healthcare remains the worst-performing sector YTD, up just 1.81%, the solid July results and positive momentum at this year's Bioshares conference signals a positive turnaround. Attended by analysts along with institutional and high net worth investors, Stockhead's Tim Boreham refers to the summit as the "Druggies & Dealers' conference – a playful nod to the well-known annual Diggers & Dealers mining forum, which this year fell in the same week. "The conference was centred on the evolution and strategic positioning of Australian biotech companies across the drug development lifecycle, with a strong emphasis on innovation and commercialisation," Power said. "We generally got the sense there is a lot more happening in the background for many of these companies than first glance." Power has highlighted nine ASX healthcare companies presenting at the summit with clear near-term catalysts over the next three to six months. Morgans nine ASX healthcare stocks with upcoming catalysts Neuren Pharmaceuticals (ASX:NEU) Market cap: $2.2 billion Neuren develops drugs for the treatment of neurological disorders and became the darling of the ASX biotech sector in 2023 when trofinetide, marketed as DAYBUE, received US Food and Drug Administration approval as the first and only approved treatment for Rett syndrome – a rare neurological disorder mostly affecting girls and emerging in infancy. Acadia Pharmaceuticals, Neuren's partner, markets DAYBUE in North America with the Aussie biotech eligible to receive double-digit royalties payments. Power said the key upcoming catalyst for Neuren would be an expectation of continued improvement in DAYBUE net sales in Q3 CY25. The company's latest quarterly sales were US$96.1 million, up 14% on pcp. CogState (ASX:CGS) Market cap: $295.9 million Cogstate is a neuroscience technology company focused on optimising neurological health assessments to advance the development of new medicines and deliver clinical insights into brain function. Its Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of neurological performance, including processing speed, attention, visual learning, working memory and executive function. CogState has provided FY25 guidance of revenue between US$52 to US$54 million, up 20% to 24% and profit before tax between US$12 to US$14 million. "CGS will report its FY25 result on August 22 with the existing share buyback expected to be extended," Power said. Market cap: $95m The key upcoming catalyst for Argenica is results forecast for early September of a phase II trial of its lead product ARG-007 in acute ischaemic stroke patients. ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours after acute neurological events such as stroke, traumatic brain injury (TBI) and hypoxic brain damage. In April, Argenica completed dosing of 92 patients in the double-blinded, randomised, placebo controlled phase II trial undertaken at eight emergency departments around Australia. Data-read out from the trial is due in September with safety the main endpoint, determining if the drug asset can advance further in clinical development. Blinklab (ASX:BB1) Market cap:$55m Blinklab is a company founded by neuroscientists at Princeton University and has developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia and other neurodevelopmental conditions. "The key short term catalyst is the release of results for BB1's pilot study for autism involving around 190 children," Power said, "The study undertaken at two sites is on track to finish recruitment in August with data locking and unblinding to follow and results expected to be released in September. "A main phase trial is expected to follow recruiting up to 900 children across eight additional sites." Clever Culture Systems (ASX:CC5) Market capitalisation $62.4 million Adelaide-based Clever Culture Systems has developed the only US FDA-cleared AI technology for automated culture plate reading. Its APAS (automated plate assessment system) Independence instruments automatically analyse culture plates to detect microbial contamination, classifying growth as significant or non-significant. In sterile drug manufacturing, culture plates are used inside cleanrooms to monitor for contamination, with results critical to releasing safe and effective drugs. Clever Culture's APAS Independence reduces the time consuming manual analysing of the culture plates by microbiologists. "CC5 has signed up three large pharmaceutical companies including AstraZeneca, Bristol Myers Squibb and Novo Nordisk plus two large lab companies and is in negotiations with other tier one groups," Power said. "Announcements around additional customers or expansion with existing customers is a key short-term catalyst." Tetratherix (ASX:TTX) Market cap: $215 million Wound management house Tetratherix made its ASX debut on June 30, breaking an IPO drought for the sector. Barrenjoey Markets and Morgans Financial were joint lead managers and underwriters to the Tetratherix IPO. Tetratherix has developed a proprietary polymer platform enabling the targeted delivery of cells, drugs and biologics, to treat a range of conditions across tissue spacing, bone regenerative and tissue healing. The company will post its maiden FY25 result in late August. "The near-term catalysts we expect to be called out include progress on the bone regeneration franchise which is targeting FDA clearance in H2 CY26 and an update on the recruitment in the trial for Cohort 2 using TetraDerm (tissue healing) involving surgical incisions in the face and neck," Power said. Micro-X (ASX:MX1) Market cap: $52 million Micro-X has proprietary cold cathode, carbon nanotube (CNT) emitter technology which is focused on medical imaging and security applications. The company recently announced a significant commercial milestone, a three-year supply agreement with a major US healthcare provider for its Rover Plus mobile radiology system. The deal followed a successful evaluation and competitive tender by the healthcare provider, which operates more than 700 facilities nationwide. It has added Rover Plus to its approved procurement list, allowing member hospitals to purchase the system without further evaluation or tendering. "We expect additional supply agreements will be executed over the near-term," Power said. Dimerix (ASX:DXB) Market cap: $300m Dimerix's lead drug candidate DMX-200 is in a phase III trial for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The ACTION3 phase III trial continues to recruit across clinical sites globally, with more than 190 sites activated. Full targeted recruitment of 286 patients for the ACTION3 trial is expected to be completed by the end of CY25. Dimerix is also developing DMX-700 for respiratory disease. "Following a positive interim analysis (Part 1) another interim analysis (Part 2) is expected to be released late CY25 or early CY26," Power said. Artrya (ASX:AYA) Market cap: $148m Artrya is developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software called Salix analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya has three key modules in its Salix platform. The FDA-cleared and launched Coronary Anatomy module is already in market. Power said upcoming catalysts for the company included FDA clearances of its Coronary Plaque module, expected in Q3 CY25, and its Coronary Flow module, anticipated in Q1 CY26. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Sydney Morning Herald
6 hours ago
- Sydney Morning Herald
Wall Street drifts around its records following a worldwide rally
US stocks are drifting around their record levels on Wednesday after a rally spurred by hopes for lower US interest rates wrapped around the world. The S&P 500 rose 0.2 per cent, coming off its latest all-time high. The Dow Jones was up 412 points, or 0.9 per cent, while the Nasdaq composite rose 0.1 per cent after setting its own record the day before. The Australian sharemarket is set to jump, with futures at 4.57am AEST pointing to a rise of 33 points, or 0.4 per cent, at the open. The ASX shed 0.6 per cent on Wednesday. The Australian dollar was 0.2 per cent stronger to US65.41¢ at 5.11am. Reporting season continues, with Westpac and Suncorp among those due up on Thursday. Treasury yields eased in the bond market as expectations reached a virtual consensus that the Federal Reserve will cut its main interest rates for the first time this year at its next meeting in September. Lower rates can boost investment prices and the economy by making it cheaper for US households and businesses to borrow to buy houses, cars or equipment, though they risk worsening inflation. Stock indexes jumped in Asia in their first trading after Tuesday's better-than-expected report on US inflation triggered a jump in bets that a cut to interest rates is coming. Hong Kong's Hang Seng leaped 2.6 per cent, Japan's Nikkei 225 rallied 1.3 per cent and South Korea's Kospi climbed 1.1 per cent. Indexes also rose in Europe, though the moves were more modest after they already had the chance to trade on the US inflation data the afternoon before. Germany's DAX returned 0.7 per cent, and France's CAC 40 rose 0.7 per cent. Loading On Wall Street, the hopes for lower interest rates are helping to drown out criticism that the US stock market has grown too expensive after its big leap since hitting a low in April. One way companies can make their stock prices look less expensive is to deliver strong growth in profits, and Brinker International became the latest to report stronger results for the latest quarter than analysts expected. The company behind the Chili's brand said it saw more customers coming to its restaurants, and it's also making more profit off each $1 in sales.
